#Leriglitazone #cerebraladrenoleukodystrophy #cALD #CerebralALD #neurologicaldisorder #neurology #CNS
#MinoryxTherapeutics #Neuraxpharm #NEXUStrial #NEXUSclinicaltrial #CerebralALD #CerebralALDpatients #oncedailyoralleriglitazone #brainlesions #cALDstudies
pharmatimes.com/news/lerigli...
#MinoryxTherapeutics #Neuraxpharm #NEXUStrial #NEXUSclinicaltrial #CerebralALD #CerebralALDpatients #oncedailyoralleriglitazone #brainlesions #cALDstudies
pharmatimes.com/news/lerigli...
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy - PharmaTimes
Promising results set stage for European marketing authorization
pharmatimes.com
December 12, 2024 at 11:50 AM